Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-1607 · 2 trials · 3 indications
Adverse events
Adverse events, laboratory abnormalities, ECGs, and vital sign measurements.
| Arm | Type | Description |
|---|---|---|
| TD-1607 or placebo (Dose1) | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| TD-1607 or placebo (Dose 2) | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| TD-1607 or placebo (Dose 3) | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| TD-1607 or placebo (Dose 4) | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| TD-1607 or placebo (Dose 5) [Optional] | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| TD-1607 or placebo (Dose 6) [Optional] | EXPERIMENTAL | TD-1607 or placebo administered intravenously |
| Active | EXPERIMENTAL | Single escalating doses of TD-1607, administered intravenously |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| TD-1607 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Subject is a healthy nonsmoking male or a female (of non-childbearing potential) and 18 to 55 years old, inclusive, at Screening. * Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least 50 kg. Subject has no clinically significant abnormalities...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
TD-1607 is an investigational small molecule being developed for infections, specifically serious infections due to known or suspected Gram-positive pathogens. It is in Phase 1 clinical development and is not yet approved by the FDA.
TD-1607 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TBPH.
TD-1607 is in Phase 1 clinical development. It has completed two Phase 1 trials in healthy subjects, and it remains an investigational drug that has not been approved for any use.
TD-1607 has completed two Phase 1 trials in healthy subjects. The first, NCT01791049, was a single ascending dose study with 64 participants. The second, NCT01949103, was a multiple ascending dose study with 48 participants. Both were conducted in the United States.
No alternative names for TD-1607 have been disclosed. It is identified solely by its developmental code TD-1607 in clinical trial registrations.